Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

101.13 +0.95 (+0.95%)
Official Closing Price Updated: 7:00 PM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,286,684
Open 100.28
Bid (Size) 101.07 (1)
Ask (Size) 101.14 (2)
Prev. Close 100.18
Today's Range 99.80 - 101.17
52wk Range 96.36 - 119.65
Shares Outstanding 2,531,374,696
Dividend Yield 2.89%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Analyst Ratings for Merck & Co
Via Benzinga
AWS and Accenture Help Merck Use Cloud Technology to Reduce Drug Discovery Time and Accelerate Clinical Trial Development
From Amazon.com, Inc.
Via Business Wire

Performance

YTD
-9.01%
-9.01%
1 Month
-1.51%
-1.51%
3 Month
-8.06%
-8.06%
6 Month
-7.36%
-7.36%
1 Year
-6.75%
-6.75%

More News

Read More
PFAS's Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Merck Announces First-Quarter 2024 Dividend
From Merck & Co., Inc.
Via Business Wire
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
Via Benzinga
Merck’s V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults, Demonstrated Superior Immunogenicity for 10 of 11 Unique Serotypes Compared to PCV20 in Adults 50 Years of Age and Older
From Merck & Co., Inc.
Via Business Wire
Biotech And Healthcare Portfolio Playbook For December 2023/24
Via Talk Markets
Stability Seekers: 7 Low-Volatility Stocks for Uncertain Times
Via InvestorPlace
Merck's Caraway Deal: Analyst Says "Timely, Anchored By Novel Programs & Management Team"
Via Benzinga
Merck to Acquire Caraway Therapeutics, Inc.
From Merck & Co., Inc.
Via Business Wire
Three Solid Stocks That Still Have Plenty Of Growth Left
Via Talk Markets
Merck to Participate in the 6th Annual Evercore ISI HealthCONx Conference
From Merck & Co., Inc.
Via Business Wire
Merck's Latest Drug For Chronic Cough Faces FDA Pushback
Via Benzinga
Exposures Product Safety
FDA Approves Merck's Blockbuster Cancer Drug For Type Of Gastric Cancer
Via Benzinga
Exposures Product Safety
Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion
Via Benzinga
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Locally Advanced Unresectable or Metastatic HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Merck's Gefapixant Under FDA Lens: Advisory Committee To Discuss Chronic Cough Drug's Future
Via Benzinga
Exposures Product Safety
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
Via Benzinga
Exposures Product Safety
2 Healthcare Stocks That Could Make You Richer
Via The Motley Fool
Global Oncology Drugs Market Size Projected to Reach $484 Billion by 2030
Via FinancialNewsMedia
The 3 Best Defensive Stocks for Uncertain Times
Via InvestorPlace
3 S&P stocks with growth to weather a downturn
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.